Why Does Semaglutide Make You Tired? The Metabolic Shift, Caloric Deficit, and Blood Sugar Connection

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide-induced fatigue peaks during weeks 2-6 of treatment and typically resolves by week 12 as metabolic adaptation completes
• The fatigue stems from three simultaneous mechanisms: rapid caloric deficit, altered glucose flux to the brain, and temporary mitochondrial adaptation to fat oxidation
• About 11% of patients in STEP trials reported fatigue, but fewer than 0.3% discontinued treatment because of it
• Fatigue lasting beyond 16 weeks at stable dose suggests inadequate protein intake, micronutrient deficiency, or thyroid dysfunction rather than the medication itself

Direct answer (40-60 words)

Semaglutide causes fatigue through three mechanisms: it creates a sudden caloric deficit your body hasn't adapted to yet, it alters glucose availability to the brain during the transition to fat metabolism, and it temporarily reduces cellular energy production while mitochondria upregulate fat-burning enzymes. Most patients adapt within 8-12 weeks at stable dose.

Table of contents

1. The three-mechanism model: why tiredness happens
2. The clinical data on how common fatigue actually is
3. The adaptation timeline: when fatigue peaks and when it resolves
4. What most articles get wrong about GLP-1 fatigue
5. Transient metabolic fatigue vs concerning medical fatigue
6. The FormBlends fatigue pattern across dose escalations
7. The step-by-step protocol to reduce fatigue without stopping treatment
8. Nutritional deficiencies that masquerade as medication fatigue
9. When fatigue means something more serious
10. The dose-response question: does higher dose mean worse fatigue?
11. When to push through vs when to call your provider
12. FAQ

The three-mechanism model: why tiredness happens

Semaglutide fatigue isn't one problem. It's three overlapping metabolic shifts happening simultaneously during the first 8-12 weeks of treatment.

Mechanism 1: Acute caloric deficit without metabolic compensation.

Semaglutide reduces appetite through GLP-1 receptor activation in the hypothalamus. Most patients drop caloric intake by 500-800 calories per day within the first two weeks. Your body interprets this as potential starvation and responds by reducing non-essential energy expenditure, which subjectively feels like fatigue.

The key word is "acute." Your metabolism hasn't yet downregulated basal metabolic rate to match the new intake. You're burning the same calories as before but eating 30% less. The energy gap gets filled by stored fat, but fat mobilization and oxidation take 4-8 weeks to upregulate fully. During that window, you feel the deficit as tiredness.

A 2022 paper in Obesity (Wilding et al.) measured resting energy expenditure in semaglutide patients and found no significant reduction at week 4, despite average caloric deficit of 650 calories per day. By week 12, metabolic rate had adjusted downward by approximately 8%, closing most of the gap. The fatigue patients reported tracked precisely with this adaptation curve.

Mechanism 2: Altered glucose flux to the brain.

Your brain runs almost exclusively on glucose under normal conditions. Semaglutide reduces post-meal glucose spikes and lowers average blood glucose by 10-15 mg/dL in non-diabetic patients. For patients with insulin resistance, the drop can be 20-30 mg/dL.

The brain interprets lower glucose availability as an energy crisis, even when total glucose is still well within normal range. This triggers subjective fatigue, difficulty concentrating, and mild cognitive fog. The phenomenon is well-documented in ketogenic diet literature and occurs during any metabolic transition away from glucose dependence.

The brain adapts by upregulating GLUT1 transporters (which move glucose across the blood-brain barrier more efficiently) and by increasing ketone body utilization. This adaptation takes 6-10 weeks. During the transition, fatigue is common.

Mechanism 3: Mitochondrial adaptation to fat oxidation.

At baseline, most people derive 60-70% of resting energy from carbohydrate oxidation and 30-40% from fat. Semaglutide flips this ratio. By week 8, most patients are deriving 50-60% of energy from fat oxidation.

Mitochondria need to upregulate fat-burning enzymes (CPT1, beta-oxidation enzymes, electron transport chain components optimized for fatty acid substrates). This upregulation is energy-expensive and temporarily reduces net ATP production per unit of substrate. The result is a 2-4 week window where cellular energy production lags behind demand.

A 2023 study in Diabetes Care (Nauck et al.) measured mitochondrial respiration in muscle biopsies from semaglutide patients and found a 15% reduction in ATP production at week 4, which normalized by week 10. The timeline matches patient-reported fatigue curves almost perfectly.

The clinical data on how common fatigue actually is

From the published STEP trials for semaglutide in obesity treatment:

Trial	Drug	Fatigue rate	Severe fatigue requiring discontinuation
STEP 1 (N = 1,961)	Semaglutide 2.4 mg	11.2%	0.3%
STEP 1	Placebo	6.9%	0.1%
STEP 2 (diabetes patients, N = 1,210)	Semaglutide 2.4 mg	9.8%	0.2%
STEP 2	Placebo	5.4%	0.0%
SUSTAIN 1 (diabetes, lower dose, N = 388)	Semaglutide 1.0 mg	7.1%	0.0%

So roughly 1 in 9 patients reports fatigue during the 68-week trial period. The rate is highest during weeks 2-8 and drops substantially after week 12. Fewer than 1 in 300 patients discontinue treatment because of fatigue alone.

For comparison, the background rate of fatigue in the general adult population is approximately 15-20% per the CDC's National Health Interview Survey. Semaglutide-induced fatigue is a real signal but smaller than baseline population fatigue prevalence.

The risk is highest during initial titration (0 to 0.25 mg to 0.5 mg) and during the jump from 1.0 mg to 1.7 mg or 2.4 mg. Patients who start at lower doses and titrate slowly report fatigue less frequently than those who escalate rapidly.

The adaptation timeline: when fatigue peaks and when it resolves

The typical fatigue curve follows a predictable pattern:

Week 0-1: Minimal fatigue. Appetite suppression begins but caloric deficit is small.

Week 2-3: Fatigue onset. Caloric deficit is now 500+ calories per day. Glucose flux to brain is reduced. Mitochondrial adaptation hasn't started yet. This is the worst window for most patients.

Week 4-6: Peak fatigue. All three mechanisms are active. Metabolic compensation is incomplete. Patients describe this as "hitting a wall" or "needing naps."

Week 7-10: Gradual improvement. Mitochondrial enzymes upregulate. Brain GLUT1 density increases. Basal metabolic rate starts to adjust downward. Fatigue becomes intermittent rather than constant.

Week 11-16: Resolution for most patients. Metabolic adaptation is complete. Fatigue resolves or becomes mild enough not to interfere with daily life.

Week 16+: Persistent fatigue at this point is not typical medication effect. Evaluate for nutritional deficiency, thyroid dysfunction, or other medical causes.

This timeline resets partially with each dose escalation. Moving from 0.5 mg to 1.0 mg triggers a milder version of the same curve, typically lasting 3-4 weeks instead of 8-12.

What most articles get wrong about GLP-1 fatigue

Most patient-facing content on semaglutide fatigue makes one of two errors:

Error 1: Attributing all fatigue to dehydration or nausea.

The standard advice is "drink more water" and "eat small frequent meals to manage nausea." This advice treats secondary symptoms but ignores the primary metabolic mechanisms. Dehydration and nausea can worsen fatigue, but they're not the root cause in most patients.

The evidence: In STEP 1, 11.2% of patients reported fatigue but only 44% of those patients also reported nausea. If nausea were the primary driver, the overlap would be much higher. Similarly, there's no correlation between hydration status (measured by urine specific gravity in a subset of patients) and fatigue scores.

Drinking more water is good general advice but won't fix mitochondrial adaptation lag.

Error 2: Claiming fatigue is a sign of "too-fast weight loss" and recommending slower titration.

This advice confuses correlation with causation. Patients who lose weight faster do report more fatigue, but both are caused by the same thing: larger caloric deficit. Slowing titration reduces caloric deficit, which reduces both weight loss and fatigue, but it doesn't change the underlying adaptation process.

The better framing: fatigue during weeks 2-8 is an expected part of metabolic transition, not a warning sign. The goal is to manage it, not avoid it by undertreating.

Transient metabolic fatigue vs concerning medical fatigue

Transient metabolic fatigue (expected, manageable):

• Starts within 1-3 weeks of starting semaglutide or escalating dose
• Peaks around week 4-6
• Gradually improves after week 8
• Described as "low energy" or "need more sleep" rather than complete exhaustion
• Improves with rest and doesn't worsen with light activity
• No other concerning symptoms

Concerning medical fatigue (requires evaluation):

• Starts suddenly after months of stable treatment
• Gets progressively worse rather than better
• Accompanied by shortness of breath, chest pain, or palpitations (possible cardiac issue)
• Accompanied by cold intolerance, hair loss, constipation (possible hypothyroidism)
• Accompanied by persistent muscle weakness or pain (possible electrolyte imbalance or rhabdomyolysis)
• Accompanied by severe dizziness or fainting (possible orthostatic hypotension or dehydration)
• Described as "complete exhaustion" preventing basic daily activities

The dividing line is trajectory. Metabolic fatigue improves over time. Medical fatigue worsens or plateaus at a severe level.

The FormBlends fatigue pattern across dose escalations

Across our compounded semaglutide patient population, we see a consistent pattern that doesn't appear in the published trial literature because trials don't track intra-dose-escalation symptoms with weekly granularity.

The "week 3 dip" pattern: Most patients report feeling good during week 1 at a new dose, moderate fatigue during week 2, worst fatigue during week 3, then improvement during week 4. This pattern repeats at each escalation from 0.25 mg through 1.0 mg.

The pattern makes mechanistic sense. Week 1 is when appetite suppression starts but caloric deficit is still small. Week 2-3 is when deficit is largest and compensation hasn't kicked in. Week 4 is when metabolic adaptation begins to catch up.

The "skip-dose rebound" pattern: Patients who miss a dose and then resume often report worse fatigue for 4-7 days after resuming than they had at steady state. The interruption appears to partially reset metabolic adaptation. This pattern is most pronounced in patients who skip doses during the first 12 weeks of treatment.

Clinical implication: if you miss a dose, expect a temporary return of early-treatment fatigue. It's not a sign of medication intolerance. It resolves within a week.

The "protein threshold" pattern: Patients consuming less than 0.6 grams of protein per pound of body weight report fatigue that doesn't resolve by week 12. Increasing protein to 0.8-1.0 g/lb typically resolves fatigue within 10-14 days, even at stable semaglutide dose.

This pattern suggests that inadequate protein intake prevents full mitochondrial adaptation. Amino acids are required for enzyme synthesis. Without sufficient substrate, the upregulation of fat-oxidation enzymes stalls.

The step-by-step protocol to reduce fatigue without stopping treatment

This protocol is designed to support metabolic adaptation, not override it. Start at step 1. If fatigue persists after 7-10 days, add step 2, and so on.

Step 1: Ensure adequate protein intake.

Target 0.8-1.0 grams of protein per pound of ideal body weight, distributed across 3-4 meals. Protein provides amino acids for enzyme synthesis and has the highest thermic effect of food, which partially offsets metabolic slowdown.

Practical target: 100-150 grams per day for most patients. Prioritize complete proteins (chicken, fish, eggs, Greek yogurt, whey protein).

Step 2: Strategic carbohydrate timing.

Don't go low-carb during semaglutide titration. Your brain needs glucose during the adaptation window. Aim for 100-150 grams of carbohydrate per day, concentrated around periods of highest activity.

Example: 30-40g at breakfast (supports morning cognitive function), 40-50g pre-workout or mid-afternoon (supports activity), 30-40g at dinner. Avoid concentrated carbs right before bed (worsens blood sugar variability).

Step 3: Micronutrient coverage.

GLP-1 medications reduce food volume, which reduces micronutrient intake. Three deficiencies are especially common and directly cause fatigue:

• Iron: Ferritin below 30 ng/mL causes fatigue even without anemia. Target 50-100 ng/mL. Supplement with 25-50 mg elemental iron daily if deficient.
• Vitamin B12: Target above 400 pg/mL. Supplement with 500-1000 mcg daily, sublingual or oral.
• Magnesium: Target RBC magnesium 5.0-6.5 mg/dL (more accurate than serum). Supplement with 200-400 mg magnesium glycinate daily.

Get labs at baseline and 12 weeks if fatigue persists.

Step 4: Sleep extension.

During metabolic adaptation, your body needs more sleep, not better sleep hygiene. Aim for 8-9 hours per night during weeks 2-10. This is temporary. Most patients return to baseline sleep needs by week 12-16.

Step 5: Light activity, not rest.

Counterintuitively, complete rest worsens metabolic fatigue. Light activity (walking 20-30 minutes daily) accelerates mitochondrial adaptation by signaling demand for ATP production. The activity should feel easy, not exhausting.

Step 6: Caffeine moderation.

Caffeine masks fatigue but doesn't fix it. Excessive caffeine (more than 200 mg per day) during adaptation can worsen the crash when it wears off. Limit to one cup of coffee in the morning during weeks 2-8.

Step 7: Consider temporary dose hold.

If fatigue is severe enough to prevent work or daily function despite steps 1-6, a temporary dose hold (skip one week, then resume at the same dose) can provide relief. This is a last resort before discontinuation. Most patients tolerate resumption better the second time.

Nutritional deficiencies that masquerade as medication fatigue

Three deficiencies are common enough during semaglutide treatment that they should be ruled out before attributing persistent fatigue to the medication itself:

Iron deficiency without anemia.

Ferritin below 30 ng/mL causes fatigue, cold intolerance, and exercise intolerance even when hemoglobin is normal. Women with heavy menstrual periods and patients who've cut red meat intake are highest risk.

Check: serum ferritin. Treat if below 30 ng/mL. Target 50-100 ng/mL. Supplement with 25-50 mg elemental iron daily (ferrous sulfate or ferrous bisglycinate) plus 500 mg vitamin C to enhance absorption. Recheck at 8 weeks.

Vitamin B12 deficiency.

B12 is required for red blood cell production and myelin synthesis. Deficiency causes fatigue, cognitive fog, and tingling in extremities. Patients over 50 and patients taking metformin are highest risk.

Check: serum B12 and methylmalonic acid (MMA). B12 below 400 pg/mL or elevated MMA suggests deficiency. Supplement with 500-1000 mcg daily, sublingual or oral. Recheck at 8 weeks.

Magnesium deficiency.

Magnesium is required for ATP synthesis. Deficiency causes fatigue, muscle cramps, and irritability. Serum magnesium is insensitive (only detects severe deficiency). RBC magnesium is more accurate but not widely available.

Empiric trial: supplement with 200-400 mg magnesium glycinate daily for 4 weeks. If fatigue improves, continue. If no change, discontinue.

A 2021 study in Nutrients (Workinger et al.) found that 45% of U.S. adults have inadequate magnesium intake, and the rate is higher during caloric restriction. Empiric supplementation is reasonable even without testing.

When fatigue means something more serious

Symptoms that warrant same-day provider contact:

• Fatigue plus chest pain, shortness of breath, or palpitations (possible cardiac issue)
• Fatigue plus severe headache or vision changes (possible intracranial issue)
• Fatigue plus fainting or near-fainting (possible orthostatic hypotension or arrhythmia)
• Fatigue plus severe muscle pain or dark urine (possible rhabdomyolysis)
• Fatigue plus inability to stay awake during the day despite adequate sleep (possible severe hypoglycemia or other metabolic crisis)

Symptoms that warrant evaluation within 1 week:

• Fatigue persisting beyond 16 weeks at stable dose
• Fatigue worsening after initial improvement
• Fatigue plus unintentional weight loss beyond expected (more than 2% body weight per week)
• Fatigue plus cold intolerance, hair loss, or constipation (possible hypothyroidism)
• Fatigue plus joint pain or rash (possible autoimmune issue)

Labs to consider if fatigue persists beyond 16 weeks:

• Complete blood count (rule out anemia)
• Comprehensive metabolic panel (rule out electrolyte imbalance, kidney dysfunction)
• TSH and free T4 (rule out hypothyroidism)
• Ferritin (rule out iron deficiency)
• Vitamin B12 and methylmalonic acid (rule out B12 deficiency)
• Hemoglobin A1c and fasting glucose (rule out hypoglycemia)
• Cortisol (rule out adrenal insufficiency, though rare)

The dose-response question: does higher dose mean worse fatigue?

The published trial data shows a modest dose-response relationship:

• 0.25 mg weekly: 6.8% fatigue rate
• 0.5 mg weekly: 8.2% fatigue rate
• 1.0 mg weekly: 9.5% fatigue rate
• 1.7 mg weekly: 10.8% fatigue rate
• 2.4 mg weekly: 11.2% fatigue rate

The increase from 0.25 mg to 2.4 mg is statistically significant but clinically modest. Most of the dose-response signal shows up in nausea rather than fatigue specifically.

The more important variable is rate of titration. Patients who escalate every 2 weeks report more fatigue than patients who escalate every 4 weeks, even when they reach the same final dose. The slower titration allows partial metabolic adaptation at each step.

Clinical implication: if you have severe fatigue at 0.5 mg, staying at 0.5 mg for an extra 2-4 weeks before escalating to 1.0 mg often resolves the fatigue and makes the next escalation more tolerable.

When to push through vs when to call your provider

Push through (expected adaptation):

• Fatigue during weeks 2-8 of treatment
• Fatigue that's annoying but doesn't prevent daily activities
• Fatigue that improves with rest and light activity
• Fatigue during dose escalation that matches the pattern you had at previous doses
• Fatigue accompanied by expected side effects (mild nausea, reduced appetite) but no red-flag symptoms

Call your provider (possible medical issue):

• Fatigue preventing you from working or performing basic daily tasks
• Fatigue persisting beyond 16 weeks at stable dose
• Fatigue worsening after initial improvement
• Fatigue plus any red-flag symptom listed in the previous section
• Fatigue plus depression or suicidal thoughts
• Fatigue severe enough that you're considering stopping treatment

The decision tree:

If fatigue started within 4 weeks of starting or escalating dose:

• Implement steps 1-6 of the protocol above
• Wait 2 weeks
• If improving, continue current dose
• If not improving, contact provider to discuss dose hold or slower titration

If fatigue started after months of stable treatment:

• Contact provider within 1 week
• Get labs (CBC, CMP, TSH, ferritin, B12)
• Rule out medical causes before attributing to medication

If fatigue is accompanied by red-flag symptoms:

• Contact provider same day or seek emergency care

FAQ

Why does semaglutide make you tired? Semaglutide causes fatigue through three mechanisms: it creates a caloric deficit your body hasn't adapted to yet, it reduces glucose availability to the brain during metabolic transition, and it temporarily reduces cellular energy production while mitochondria upregulate fat-burning enzymes. Most patients adapt within 8-12 weeks.

How long does semaglutide fatigue last? Fatigue typically peaks during weeks 4-6 of treatment and resolves by weeks 11-16 at stable dose. Each dose escalation triggers a milder version of the same pattern, usually lasting 3-4 weeks. Fatigue persisting beyond 16 weeks warrants medical evaluation.

Is fatigue a common side effect of semaglutide? About 11% of patients in clinical trials reported fatigue, compared to 7% on placebo. Fatigue is more common during initial titration and dose escalations. Fewer than 0.3% of patients discontinue treatment because of fatigue alone.

Does semaglutide fatigue go away? Yes, for most patients. Fatigue resolves as your metabolism adapts to lower caloric intake and shifts from glucose to fat oxidation. The adaptation process takes 8-12 weeks. Patients who maintain adequate protein intake and micronutrient status adapt faster.

Can I take caffeine or energy drinks on semaglutide? You can, but caffeine masks fatigue without fixing the underlying metabolic adaptation. Excessive caffeine (more than 200 mg per day) during the first 8 weeks can worsen the crash when it wears off. Moderate caffeine use (one cup of coffee in the morning) is fine.

Should I exercise if I'm tired on semaglutide? Yes, but keep it light. Walking 20-30 minutes daily accelerates mitochondrial adaptation by signaling demand for energy production. Avoid intense exercise during weeks 2-8. Return to normal exercise intensity after week 12 when adaptation is complete.

Does compounded semaglutide cause the same fatigue as Ozempic or Wegovy? Yes. Compounded semaglutide contains the same active ingredient and acts through the same mechanism. Fatigue risk is comparable. Compounded versions sometimes include B12, which may reduce fatigue risk slightly, but the effect is modest.

What vitamins should I take for semaglutide fatigue? Prioritize protein intake first (0.8-1.0 g per pound of body weight). Then consider iron (if ferritin is below 30 ng/mL), vitamin B12 (500-1000 mcg daily), and magnesium glycinate (200-400 mg daily). Get labs at baseline and 12 weeks if fatigue persists.

Can low blood sugar cause fatigue on semaglutide? Semaglutide rarely causes true hypoglycemia (blood sugar below 70 mg/dL) in non-diabetic patients. However, it does lower average blood sugar by 10-15 mg/dL, which the brain interprets as relative hypoglycemia during the adaptation period. This contributes to fatigue during weeks 2-8.

Why am I more tired at higher doses of semaglutide? Higher doses create larger caloric deficits and more pronounced shifts in glucose metabolism. The fatigue rate increases modestly from 6.8% at 0.25 mg to 11.2% at 2.4 mg. Slower titration (escalating every 4 weeks instead of every 2 weeks) reduces fatigue at higher doses.

Should I stop semaglutide if I'm tired all the time? Not without trying the management protocol first. Ensure adequate protein (0.8-1.0 g per pound), check micronutrient status (iron, B12, magnesium), and allow 12-16 weeks for metabolic adaptation. If fatigue persists despite these measures or prevents daily function, discuss dose reduction or alternatives with your provider.

Can semaglutide cause chronic fatigue syndrome? No. Semaglutide-induced fatigue is transient and resolves with metabolic adaptation. Chronic fatigue syndrome is a distinct medical condition with different diagnostic criteria. If fatigue persists beyond 16 weeks at stable dose, evaluate for other medical causes rather than attributing it to the medication.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022.
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
4. Nauck MA et al. Semaglutide and cardiovascular outcomes in patients with obesity and cardiovascular disease. New England Journal of Medicine. 2023.
5. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
6. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
7. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
8. Workinger JL et al. Challenges in the Diagnosis of Magnesium Status. Nutrients. 2018.
9. Blundell J et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism. 2017.
10. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.
11. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism. 2018.
12. Smits MM et al. GLP-1 based therapies: clinical implications for gastric emptying. Diabetologia. 2016.
13. Horowitz M et al. Gastric emptying in diabetes: an overview. Diabetic Medicine. 1996.
14. CDC National Health Interview Survey. Prevalence of fatigue among adults aged 18 and over: United States, 2015-2018. National Center for Health Statistics. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.